Cancer treatment constantly evolves, and camptothecin family drugs like irinotecan and topotecan hold promise as potent anti-cancer agents. A recent study explored their cytotoxic effects in breast cancer cells and their connection to TOP1 enzyme activity.
Diverse Breast Cancer Cells
Researchers analyzed cell lines from various breast cancer subtypes, including Luminal, HER2 positive, and Triple Negative Breast Cancer (TNBC).
Chemosensitivity and TOP1 Activity
The study focused on correlating chemosensitivity with two key factors:
- Cell Division Rate: This factor revealed insights into cancer cell growth control.
- TOP1 Activity Level: Especially interesting was the link found in TNBC, a subtype notorious for its resistance.
These findings deepen our understanding of camptothecin drugs in breast cancer treatment. Tailoring therapies to specific subtypes, especially TNBC, offers hope for improved outcomes in breast cancer care. Every discovery brings us closer to more effective treatments and brighter futures for patients.
BMC cancer, 2019. Doi: 10.1186/s12885-019-6371-0